PL346700A1 - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents
Pyrrolopyrimidines as protein kinase inhibitorsInfo
- Publication number
- PL346700A1 PL346700A1 PL99346700A PL34670099A PL346700A1 PL 346700 A1 PL346700 A1 PL 346700A1 PL 99346700 A PL99346700 A PL 99346700A PL 34670099 A PL34670099 A PL 34670099A PL 346700 A1 PL346700 A1 PL 346700A1
- Authority
- PL
- Poland
- Prior art keywords
- pyrrolopyrimidines
- protein kinase
- kinase inhibitors
- inhibitors
- protein
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10083398P | 1998-09-18 | 1998-09-18 | |
| US10083498P | 1998-09-18 | 1998-09-18 | |
| US10083298P | 1998-09-18 | 1998-09-18 | |
| US10094698P | 1998-09-18 | 1998-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL346700A1 true PL346700A1 (en) | 2002-02-25 |
Family
ID=27493158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL99346700A PL346700A1 (en) | 1998-09-18 | 1999-09-17 | Pyrrolopyrimidines as protein kinase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1114053A1 (en) |
| JP (1) | JP2002526500A (en) |
| KR (1) | KR20010085824A (en) |
| CN (1) | CN1335849A (en) |
| AU (1) | AU753555C (en) |
| BG (1) | BG105346A (en) |
| BR (1) | BR9913887A (en) |
| CA (1) | CA2344249A1 (en) |
| CZ (1) | CZ2001960A3 (en) |
| HK (1) | HK1039326A1 (en) |
| HU (1) | HUP0200403A3 (en) |
| ID (1) | ID29028A (en) |
| IL (1) | IL141866A0 (en) |
| NO (1) | NO20011356L (en) |
| NZ (1) | NZ510588A (en) |
| PL (1) | PL346700A1 (en) |
| SK (1) | SK3842001A3 (en) |
| TR (1) | TR200101186T2 (en) |
| WO (1) | WO2000017203A1 (en) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
| DE69933680T2 (en) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | PYRIMIDINE COMPOUNDS |
| US6632820B1 (en) | 1998-08-29 | 2003-10-14 | Astrazeneca Ab | Pyrimidine compounds |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| EA006227B1 (en) | 1999-12-10 | 2005-10-27 | Пфайзер Продактс Инк. | PIRROLO(2,3-d)PYRIMIDINE COMPOUNDS |
| WO2001051456A2 (en) * | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| AU2000240570A1 (en) * | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| US7369946B2 (en) | 2000-03-29 | 2008-05-06 | Abbott Gmbh & Co. Kg | Method of identifying inhibitors of Tie-2 |
| EA006153B1 (en) | 2000-06-26 | 2005-10-27 | Пфайзер Продактс Инк. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| US7081454B2 (en) | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| GB0121033D0 (en) * | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (en) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Imidazolyl-substituted pyrimidine derivatives having CDK inhibitory activity |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| DE60304718T2 (en) | 2002-08-06 | 2007-04-26 | Astrazeneca Ab | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| AU2003276591A1 (en) | 2002-11-26 | 2004-06-18 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| GB0302748D0 (en) * | 2003-02-06 | 2003-03-12 | Novartis Ag | Organic compounds |
| AP2005003390A0 (en) | 2003-03-12 | 2005-09-30 | Pfizer Prod Inc | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives. |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| AR045037A1 (en) | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | TETRAHIDRO-1H-PIRAZOLO [3,4-C] SUBSTITUTED PYRIDINS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE. |
| US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
| US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2007511596A (en) * | 2003-11-17 | 2007-05-10 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine compounds useful in the treatment of cancer |
| CA2553724A1 (en) * | 2004-02-03 | 2005-08-18 | Abbott Laboratories | Aminobenzoxazoles as therapeutic agents |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| HRP20090495T1 (en) | 2004-04-02 | 2009-10-31 | Osi Pharmaceuticals | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| EP1773836B1 (en) | 2004-05-27 | 2012-09-05 | Pfizer Products Inc. | Pyrrolopyrimidine derivatives useful in cancer treatment |
| AR053090A1 (en) | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | IMIDAZOTRIAZINS AS PROTEIN KINASE INHIBITORS AND THEIR USE FOR THE PREPARATION OF MEDICINES |
| TW200626142A (en) * | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| CA2601766A1 (en) * | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| AU2006239632B2 (en) * | 2005-04-25 | 2012-03-15 | Merck Patent Gmbh | Novel AZA- heterocycles serving as kinase inhibitors |
| CA2623125A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2007036732A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| JP5116687B2 (en) * | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | Pyrrolo [2,1-f] [1,2,4] triazin-4-ylamine IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| AR057960A1 (en) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | BICYCLE PROTEIN QUINASE INHIBITORS |
| CA2641254A1 (en) * | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
| MX2008013990A (en) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof. |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| US20100190777A1 (en) | 2007-07-17 | 2010-07-29 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| HRP20140395T1 (en) | 2008-08-20 | 2014-06-06 | Zoetis Llc | PIROLO [2,3-d] PIRIMIDINE COMPOUNDS |
| CA2740885C (en) * | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
| WO2010054264A1 (en) | 2008-11-07 | 2010-05-14 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| WO2010084944A1 (en) * | 2009-01-22 | 2010-07-29 | 田辺三菱製薬株式会社 | NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010126960A1 (en) * | 2009-04-29 | 2010-11-04 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2011112666A1 (en) | 2010-03-09 | 2011-09-15 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
| CN103492390A (en) * | 2011-03-08 | 2014-01-01 | 诺瓦提斯公司 | Fluorophenyl bicyclic heteroaryl compounds |
| JP2014519813A (en) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment |
| EA201490265A1 (en) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | BLUTON TYROSINKINASE INHIBITORS |
| AU2012285987C1 (en) | 2011-07-19 | 2016-09-08 | Merck Sharp & Dohme B.V. | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as Btk- inhibitors |
| MX370814B (en) | 2011-09-02 | 2020-01-08 | Univ California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof. |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| CN104080789B (en) * | 2012-01-31 | 2016-05-11 | 南京奥昭生物科技有限公司 | Cyclic Molecules as Bruton's Tyrosine Kinase Inhibitors |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US9604988B2 (en) | 2012-07-27 | 2017-03-28 | Riken | Agent for treating or inhibiting recurrence of acute myeloid leukemia |
| MX2015003874A (en) | 2012-09-26 | 2015-12-16 | Univ California | Modulation of ire1. |
| EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancer therapy |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| ES2685661T3 (en) | 2013-11-08 | 2018-10-10 | Ono Pharmaceutical Co., Ltd. | Pyrrolopyrimidine derivative |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| CA2834528A1 (en) * | 2013-11-26 | 2015-05-26 | Pharmascience Inc. | Protein kinase inhibitors |
| CN105916859A (en) | 2014-02-03 | 2016-08-31 | 卡迪拉保健有限公司 | Heterocyclic compounds |
| RS62713B1 (en) | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor |
| EP4455145A3 (en) * | 2015-12-02 | 2025-03-12 | Astraea Therapeutics, LLC | Piperidinyl nociceptin receptor compounds |
| US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
| MX2021012639A (en) | 2016-11-18 | 2022-10-03 | Cystic Fibrosis Found | PYRROLOPYRIMIDINES AS ENHANCERS OF CFTR. |
| PL3808747T3 (en) * | 2018-09-13 | 2025-03-17 | Kissei Pharmaceutical Co., Ltd. | Imidazopyridinone compound |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| CN116348458A (en) | 2019-08-14 | 2023-06-27 | 因赛特公司 | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| CN119930611A (en) | 2019-10-11 | 2025-05-06 | 因赛特公司 | Dicyclomine as a CDK2 inhibitor |
| CN112961159B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidinopyrazole/pyrrole derivative and preparation method and application thereof |
| CN112961158B (en) * | 2020-03-05 | 2022-07-01 | 四川大学华西医院 | Aminopyrimidinopyrazole/pyrrole derivative and preparation method and application thereof |
| JP7504822B2 (en) * | 2020-03-12 | 2024-06-24 | キッセイ薬品工業株式会社 | Pharmaceutical Compositions Containing Imidazopyridinone Compounds |
| WO2021184154A1 (en) * | 2020-03-16 | 2021-09-23 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| KR20240170936A (en) * | 2022-03-31 | 2024-12-05 | 에이스랜드 테라퓨틱스 (홍콩) 리미티드 | Spirobiocyclic compounds |
| CN117402161A (en) * | 2022-07-06 | 2024-01-16 | 上海科恩泰生物医药科技有限公司 | A sulfoximine compound with FGFR inhibitory effect, pharmaceutical composition containing the same and its use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3036390A1 (en) * | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
| FI933303L (en) * | 1991-01-23 | 1993-08-31 | Gensia Inc | ADENOSINCINE INHIBITORS |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| JP4145955B2 (en) * | 1994-09-29 | 2008-09-03 | ノバルティス アクチェンゲゼルシャフト | Pyrrolo [2,3-d] pyrimidine and use thereof |
| US5665721A (en) * | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| CH690773A5 (en) * | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo (2,3-d) pyrimides and their use. |
| AU1794697A (en) * | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
| US6051577A (en) * | 1996-03-15 | 2000-04-18 | Novartis Ag | N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof |
| TR199902301T2 (en) * | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pyrilo $2,3D]pyrimidines and their use. |
-
1999
- 1999-09-17 HK HK02100227.3A patent/HK1039326A1/en unknown
- 1999-09-17 SK SK384-2001A patent/SK3842001A3/en unknown
- 1999-09-17 CN CN99813217A patent/CN1335849A/en active Pending
- 1999-09-17 CA CA002344249A patent/CA2344249A1/en not_active Abandoned
- 1999-09-17 JP JP2000574112A patent/JP2002526500A/en active Pending
- 1999-09-17 HU HU0200403A patent/HUP0200403A3/en unknown
- 1999-09-17 IL IL14186699A patent/IL141866A0/en unknown
- 1999-09-17 ID IDW20010652A patent/ID29028A/en unknown
- 1999-09-17 TR TR2001/01186T patent/TR200101186T2/en unknown
- 1999-09-17 AU AU60484/99A patent/AU753555C/en not_active Ceased
- 1999-09-17 WO PCT/US1999/021560 patent/WO2000017203A1/en not_active Ceased
- 1999-09-17 EP EP99969415A patent/EP1114053A1/en not_active Withdrawn
- 1999-09-17 KR KR1020017003532A patent/KR20010085824A/en not_active Ceased
- 1999-09-17 BR BR9913887-5A patent/BR9913887A/en not_active IP Right Cessation
- 1999-09-17 PL PL99346700A patent/PL346700A1/en unknown
- 1999-09-17 NZ NZ510588A patent/NZ510588A/en unknown
- 1999-09-17 CZ CZ2001960A patent/CZ2001960A3/en unknown
-
2001
- 2001-03-15 BG BG105346A patent/BG105346A/en unknown
- 2001-03-16 NO NO20011356A patent/NO20011356L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1114053A1 (en) | 2001-07-11 |
| NO20011356L (en) | 2001-05-16 |
| JP2002526500A (en) | 2002-08-20 |
| TR200101186T2 (en) | 2001-10-22 |
| BR9913887A (en) | 2001-10-23 |
| AU6048499A (en) | 2000-04-10 |
| KR20010085824A (en) | 2001-09-07 |
| ID29028A (en) | 2001-07-26 |
| NO20011356D0 (en) | 2001-03-16 |
| NZ510588A (en) | 2003-08-29 |
| BG105346A (en) | 2001-12-29 |
| CZ2001960A3 (en) | 2001-10-17 |
| HUP0200403A2 (en) | 2002-06-29 |
| AU753555B2 (en) | 2002-10-24 |
| HK1039326A1 (en) | 2002-04-19 |
| IL141866A0 (en) | 2002-03-10 |
| CN1335849A (en) | 2002-02-13 |
| AU753555C (en) | 2003-07-03 |
| HUP0200403A3 (en) | 2004-07-28 |
| WO2000017203A1 (en) | 2000-03-30 |
| SK3842001A3 (en) | 2002-04-04 |
| CA2344249A1 (en) | 2000-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL141866A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| HUS1700048I1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
| HUP0400300A3 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| PL346934A1 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
| AU6411698A (en) | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors | |
| EP1066286A4 (en) | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors | |
| AP2000001861A0 (en) | Bicylic heteroaromatic compounds as protein tyrosine kinase inhibitors | |
| AU5173400A (en) | Protein kinases | |
| IL146094A0 (en) | Diaminothiazoles and their use for inhibiting protein kinases | |
| IL141724A0 (en) | INHIBITORS OF P38-α KINASE | |
| HUP0202713A3 (en) | Pteridinones as kinase inhibitors | |
| AU2437900A (en) | Piperidinylquinolines as protein tyrosine kinase inhibitors | |
| AU2000240570A1 (en) | Pyrrolopyrimidines as tyrosine kinase inhibitors | |
| IL159506A0 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| AU2001237041A1 (en) | Kinase inhibitors | |
| AU2001247882A1 (en) | Tricyclic protein kinase inhibitors | |
| AU6882598A (en) | Protein kinase inhibitor | |
| AU2576501A (en) | Protein kinase inhibitors | |
| AU6049399A (en) | Serine/threonine protein kinases | |
| AU2591299A (en) | Human protein kinase c inhibitor | |
| GB9803399D0 (en) | Protein kinase c | |
| AU1800700A (en) | Ikk3 kinase | |
| AU3097299A (en) | Nek1-related protein kinase | |
| HK1035187A (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | |
| GB9806743D0 (en) | Cyclin dependent kinase inhibitors |